ScoreWhy is Xilio Therapeutics, Inc. ?
1
With a growth in Net Sales of 131.22%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 10 consecutive quarters
- NET SALES(Q) At USD 18.69 MM has Grown at 131.22%
- ROCE(HY) Highest at -55.03%
- RAW MATERIAL COST(Y) Fallen by -3.12% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -15.59%, its profits have risen by 28.7%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -2.59% over the previous quarter and currently hold 31.41% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -15.59% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Xilio Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xilio Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xilio Therapeutics, Inc.
-14.45%
0.53
1431.35%
S&P 500
15.76%
1.22
13.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
113.89%
EBIT Growth (5y)
4.24%
EBIT to Interest (avg)
-64.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.21
Sales to Capital Employed (avg)
-0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
62.34%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.36
EV to EBIT
2.10
EV to EBITDA
2.18
EV to Capital Employed
0.87
EV to Sales
-2.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
41.60%
ROE (Latest)
-115.90%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
NET SALES(Q)
At USD 18.69 MM has Grown at 131.22%
ROCE(HY)
Highest at -55.03%
RAW MATERIAL COST(Y)
Fallen by -3.12% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 21.36 times
PRE-TAX PROFIT(Q)
At USD -2.43 MM has Grown at 84.6%
NET PROFIT(Q)
At USD -2.43 MM has Grown at 84.6%
-3What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -60.6 MM
DEBT-EQUITY RATIO
(HY)
Highest at -179.53 %
Here's what is working for Xilio Therapeutics, Inc.
Net Sales
At USD 18.69 MM has Grown at 131.22%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD -2.43 MM has Grown at 84.6%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -2.43 MM has Grown at 84.6%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 21.36 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -3.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Xilio Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -60.6 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -179.53 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Footer loading
